Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance

RAPID MICRO BIOSYSTEMS, INC.

2023-Q2 EPS reported -$0.65 revenue$10,037,000

Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).
Recurring revenue $3.6M, up 44% YoY; record consumable revenue; placed two new Growth Direct systems.
Cash, cash equivalents and investments $113.3M as of June 30, 2023; no debt; cash runway into 2026.
Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 system placements.
Appointed Kirk Malloy, Ph.D. as Chair of the Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

RAPID MICRO BIOSYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue $5.0 million. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $5.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-23-000142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.